This presentation will present all of the head-to-head clinical trials conducted on antiplatelet agents in the setting of acute coronary syndrome. After presenting the ISAR-REACT trial, pharmacists will understand why prasugrel is the preferred agent in select populations based on the methods and outcomes of this trial. We will close the knowledge gap pertaining to anticoagulants in the setting of ACS and how to address triple therapy by discussing the current ACC/AHA guidelines as well as discuss the most recent literature published about discontinuing antiplatelet therapy in our patients who have stable ischemic heart disease. The presentation will include a discussion on the potential role of anticoagulants for the secondary prevention of acute coronary syndrome outside of patients with atrial fibrillation.